View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 29, 2021

SHINE Medical secures $150m to support isotope technologies

The company produces diagnostic isotope molybdenum-99 and therapeutic isotope lutetium-177.

SHINE Medical Technologies has secured $150m in a Series C-5 funding round to support the marketing of its medical isotope technologies developed for diagnostic and therapeutic applications.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

The funds will also be used to develop new applications by leveraging fusion-based technologies.

Koch Disruptive Technologies led the financing, which was joined by Fidelity Management & Research Company and Baillie Gifford, as well as additional new and existing investors.

Koch Disruptive Technologies president Chase Koch said: “SHINE’s innovative medical isotope technologies, which play a crucial role in identifying and treating patients with debilitating diseases, are astounding.

“We believe SHINE has the potential to change not only the production and supply of medical isotopes, but to transform industrial segments globally by leveraging the company’s nuclear-fusion based technology for industrial inspection and imaging, nuclear waste recycling and energy production.”

At its current facility, SHINE manufactures the therapeutic medical isotope lutetium-177 (Lu-177).

Radiotherapeutics have the potential to treat various cancers owing to their direct irradiation of cancer, even at the late stages, the company noted.

Using its manufacturing process, the company can generate Lu-177 with high-specific activity, the isotope’s form that is currently most in demand by clinical trial sponsors.

Last December, SHINE began constructing a large-scale therapeutic isotope plant. This site is scheduled to begin operations next year and will manufacture Lu-177.

The company is additionally setting up a fusion-based medical isotope manufacturing plant in Janesville, Wisconsin, US, to make molybdenum-99 (Mo-99), which is used to diagnose heart disease, cancer and various other conditions.

Mo-99 is required for more than 40 million patient procedures annually.

Due to low Mo-99 production, the US has a chronic scarcity of the isotope. SHINE’s facility is expected to have the capacity to supply more than 33% of the worldwide demand for the isotope.

In May, SHINE announced plans for a new medical isotope production facility in Europe. Together the US and European plants will allow the company to produce 70% of the global Mo-99 demand.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU